Anti-alpha-v integrin antibody for the treatment of fibrosis and/or fibrotic disorders

US12054549B2 · kind B2 · utility

Assignee

• Merck Patent GmbH · DE

Inventors

• Ilhan Celik · Zwingenberg, DE
• Eike Staub · Darmstadt, DE
• Miriam Urban · Leidersbach, DE
• Sabine Raab-Westphal · Rosbach, DE
• Eileen Samy · Arlington, US
• Andrew Bender · Reading, US
• Georgianna Varrone · Tewksbury, US
• Yin Wu · Andover, US
• Daigen Xu · Ottawa, CA

Key dates

• Filing date: Oct 28, 2022
• Grant date: Aug 6, 2024
• Expiry date: Oct 28, 2042

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/76
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A method can treat a patient suffering from at least one of fibrosis and a fibrotic disorder. The method includes administering a therapeutically effective amount of an anti-αv integrin antibody DI17E6, or a biologically active variant or modification thereof, to the patient.